Tigecylcine warning from the FDA

The IV antibiotic tigecycline received a label change and warning from the FDA, given the drug has been associated with higher mortality than similar broad spectrum antibiotics. Although a mechanism for the higher mortality has not been elucidated, the FDA is recommending the use of alternative antibiotics, rather than tigecycline, in hospitalized patients wtih serious infections (FDA site)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment